AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21745115 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (TURP)
Number of subjects: 60
Study 19915222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 5362
Study 19915222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5362
Study 17323591 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 12092
Study 17323591 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo or unfractionated heparin)
Number of subjects: 12092
Study 12641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 2288
Study 12641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir on formulary
Number of subjects: 2288
Study 11052557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill organizer
Number of subjects: 481
Study 11052557 — intervention group
Group type: COMPARATOR
Intervention: No organizer
Number of subjects: 481
Study 11052557 — intervention group
Group type: EXPERIMENTAL
Intervention: Blister packs
Number of subjects: 481
Study 11052557 — intervention group
Group type: COMPARATOR
Intervention: Pill organizers
Number of subjects: 481
Study 11052557 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplements
Number of subjects: 481
Study 11052557 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 481
Study 9110907 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 220
Study 9110907 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone
Number of subjects: 220
Study 9110907 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan, prednisone, and colchicine
Number of subjects: 220
Study 9110907 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in serum or urine monoclonal protein at 12 months
Number of subjects: 220
Study 9110907 — intervention group
Group type: EXPERIMENTAL
Intervention: No reduction in serum or urine monoclonal protein at 12 months
Number of subjects: 220
Study 9110907 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival of patients
Number of subjects: 220
Study 8257409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 36
Study 8257409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naltrexone
Number of subjects: 36
Study 8257409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 4007041 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 59
Study 4007041 — intervention group
Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 59
Study 31095810 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted single-phase (DS; 1.6 ml/s)
Number of subjects: 40
Study 31095810 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted biphasic (DB; 9 ml @ 3.3 ml/s, 29 ml @ 1.4 ml/s)
Number of subjects: 40
Study 31095810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored protocol using linear prediction (DT)
Number of subjects: 40
Study 31095810 — intervention group
Group type: COMPARATOR
Intervention: Nondiluted single-phase (NS; 1.6 ml/s)
Number of subjects: 40
Study 29098260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided superior laryngeal nerve block and cricothyroid membrane puncture (Group U)
Number of subjects: 30
Study 29098260 — intervention group
Group type: COMPARATOR
Intervention: Anatomical location group (Group A)
Number of subjects: 30
Study 26716735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 500
Study 26716735 — intervention group
Group type: COMPARATOR
Intervention: No intra-arterial treatment (Control)
Number of subjects: 500
Study 24357015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg QD
Number of subjects: 0
Study 24357015 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 22978083 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg)
Number of subjects: 60
Study 22978083 — intervention group
Group type: COMPARATOR
Intervention: Lithium (control group)
Number of subjects: 60
Study 20538417 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 126
Study 20538417 — intervention group
Group type: COMPARATOR
Intervention: Health Group (HG)
Number of subjects: 126
Study 17944770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg intravenous infusion
Number of subjects: 73
Study 17944770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16127404 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit consumption
Number of subjects: 58
Study 16127404 — intervention group
Group type: COMPARATOR
Intervention: Diseased control group
Number of subjects: 58
Study 11802224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary interventions (psychosocial strategies, nursing approaches, psychotropic medications, management of pain)
Number of subjects: 99
Study 11802224 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 99
Study 11802224 — intervention group
Group type: COMPARATOR
Intervention: Late intervention group
Number of subjects: 99
Study 10425672 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support calls by social workers (professional team)
Number of subjects: 93
Study 10425672 — intervention group
Group type: COMPARATOR
Intervention: Telephone support calls by secretarial staff (nonprofessional team)
Number of subjects: 93
Study 7585237 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 73
Study 7585237 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual function tests
Number of subjects: 73
Study 7585237 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCS III
Number of subjects: 73
Study 7585237 — intervention group
Group type: EXPERIMENTAL
Intervention: CCD
Number of subjects: 73
Study 2266237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 69
Study 2266237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 6998239 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 405
Study 6998239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 31418950 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day
Number of subjects: 80
Study 31418950 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 28319673 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast for 12 weeks
Number of subjects: 58
Study 28319673 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 58
Study 26012297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with azelastine and fluticasone propionate
Number of subjects: 162
Study 26012297 — intervention group
Group type: COMPARATOR
Intervention: Nasal corticosteroids monotherapy
Number of subjects: 162
Study 24228935 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 0
Study 24228935 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20237778 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral TKA
Number of subjects: 40
Study 20237778 — intervention group
Group type: COMPARATOR
Intervention: Unilateral TKA
Number of subjects: 40
Study 20031582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 5745
Study 20031582 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate gene analysis of 23 genes
Number of subjects: 5745
Study 20031582 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome analysis
Number of subjects: 5745
Study 20031582 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender influence
Number of subjects: 5745
Study 18757661 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension or pubovaginal sling surgery for SUI in older women (≥65 years)
Number of subjects: 655
Study 15316717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 4 weeks
Number of subjects: 18
Study 12140020 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep lamellar keratoplasty (DLKP)
Number of subjects: 24
Study 12140020 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 24
Study 10190777 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (60+/‐4% of maximal heart rate)
Number of subjects: 21
Study 10190777 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (84+/‐4% of maximal heart rate)
Number of subjects: 21
Study 10190777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 7802268 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating bulb (SIB) used with blind insertion of ETC (Group 1)
Number of subjects: 46
Study 7802268 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating bulb (SIB) used with direct vision placement of ETC (Group 2)
Number of subjects: 46
Study 2103531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendazac-lysine salt
Number of subjects: 0
Study 2103531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7387336 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human beta-endorphin infusion
Number of subjects: 18
Study 7387336 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 7387336 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-endorphin treatment
Number of subjects: 18
Study 30180860 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP delivery integrated in HIV care clinics; includes staff training, streamlined access to PrEP commodities, and ongoing technical assistance.
Number of subjects: 24
Study 30180860 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP service delivery conducted by clinic staff with no additional resources from the project.
Number of subjects: 24
Study 30180860 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation science evaluation using the RE-AIM framework.
Number of subjects: 24
Study 30180860 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-wedge, cluster-randomized trial design.
Number of subjects: 24
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual nonoperative care for symptomatic LDH
Number of subjects: 478
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete initial resolution of leg pain
Number of subjects: 478
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete initial resolution of LBP
Number of subjects: 478
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete leg pain resolution
Number of subjects: 478
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral herniation location
Number of subjects: 478
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint problems
Number of subjects: 478
Study 26548963 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 478
Study 24460405 — intervention group
Group type: EXPERIMENTAL
Intervention: Music adapted to brain rhythm anomalies associated with psychoticism
Number of subjects: 50
Study 24460405 — intervention group
Group type: COMPARATOR
Intervention: Standard classical music
Number of subjects: 50
Study 23059574 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate (Novamin SHY NM) dentifrice
Number of subjects: 30
Study 23059574 — intervention group
Group type: COMPARATOR
Intervention: Pepsodent toothpaste without a desensitizing agent
Number of subjects: 30
Study 20974325 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablet (20 mg)
Number of subjects: 21
Study 20974325 — intervention group
Group type: EXPERIMENTAL
Intervention: Test capsule (20 mg)
Number of subjects: 21
Study 20974325 — intervention group
Group type: COMPARATOR
Intervention: Reference tablet (20 mg)
Number of subjects: 21
Study 18577912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 60
Study 18577912 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study 16649836 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 25
Study 16649836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12490494 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive radiofrequency ablation
Number of subjects: 97
Study 12490494 — intervention group
Group type: COMPARATOR
Intervention: Standard radiofrequency ablation
Number of subjects: 97
Study 12490494 — intervention group
Group type: EXPERIMENTAL
Intervention: Power rolloff achieved
Number of subjects: 97
Study 12490494 — intervention group
Group type: EXPERIMENTAL
Intervention: No power rolloff
Number of subjects: 97
Study 10228298 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula (579 31 mL/d)
Number of subjects: 93
Study 10228298 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy allergy determination
Number of subjects: 93
Study 10228298 — intervention group
Group type: COMPARATOR
Intervention: Soy formula
Number of subjects: 93
Study 8604728 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival 5‐fluorouracil injections after trabeculectomy
Number of subjects: 213
Study 8604728 — intervention group
Group type: COMPARATOR
Intervention: Standard filtering surgery (trabeculectomy alone)
Number of subjects: 213
Study 1778087 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg) - Spironolactone (100 mg) formulation 1
Number of subjects: 12
Study 1778087 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg) - Spironolactone (100 mg) formulation 2
Number of subjects: 12
Study 1778087 — intervention group
Group type: COMPARATOR
Intervention: Pharmacodynamic parameters
Number of subjects: 12
Study 7376041 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% albumin
Number of subjects: 11
Study 7376041 — intervention group
Group type: COMPARATOR
Intervention: lactated Ringer's solution
Number of subjects: 11
Study 30249374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg/day) for 2 weeks after surgery
Number of subjects: 100
Study 30249374 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks after surgery
Number of subjects: 100
Study 27921185 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo
Number of subjects: 180
Study 27921185 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + adalimumab
Number of subjects: 180
Study 27921185 — intervention group
Group type: EXPERIMENTAL
Intervention: HBL6months
Number of subjects: 180
Study 25818679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol or Lisinopril
Number of subjects: 179
Study 24212988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Gen with connective tissue
Number of subjects: 24
Study 24212988 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Gen with Biocollagen
Number of subjects: 24
Study 21357307 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing among men aged 40-54 years
Number of subjects: 0
Study 21357307 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing among men aged 55-74 years
Number of subjects: 0
Study 21357307 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing among men older than 75 years
Number of subjects: 0
Study 20093332 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG)
Number of subjects: 44
Study 20093332 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound treatment (Control)
Number of subjects: 44
Study 17141582 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (Bu)
Number of subjects: 0
Study 17141582 — intervention group
Group type: EXPERIMENTAL
Intervention: Norbuprenorphine (norBu)
Number of subjects: 0
Study 17141582 — intervention group
Group type: EXPERIMENTAL
Intervention: Method validation
Number of subjects: 0
Study 15023578 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measuring oxyhemoglobin concentrations during word fluency and finger tapping tasks.
Number of subjects: 39
Study 15023578 — intervention group
Group type: COMPARATOR
Intervention: Near-infrared spectroscopy (NIRS) measuring oxyhemoglobin concentrations during finger tapping task.
Number of subjects: 39
Study 11374599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of oral lorazepam the night before surgery and 5 mg of intramuscular midazolam on the morning of surgery
Number of subjects: 70
Study 11374599 — intervention group
Group type: COMPARATOR
Intervention: Placebo the night before surgery and on the morning of surgery
Number of subjects: 70
Study 11374599 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 70
Study 9040266 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen plug (Vasoseal)
Number of subjects: 62
Study 9040266 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 62
Study 8124144 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum cholesterol concentration (below 5 mmol/l)
Number of subjects: 687
Study 8124144 — intervention group
Group type: COMPARATOR
Intervention: Randomised trials (specific treatments for lowering cholesterol)
Number of subjects: 687
Study 8124144 — intervention group
Group type: COMPARATOR
Intervention: Community cohorts with low cholesterol
Number of subjects: 687
Study 3300383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 doses)
Number of subjects: 107
Study 3300383 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin (2 doses)
Number of subjects: 107
Study 3300383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (both doses)
Number of subjects: 107
Study 31549208 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC implantation
Number of subjects: 80
Study 31549208 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC implantation with allogenic cartilage
Number of subjects: 80
Study 30309244 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH2 rs4570625 (T-allele carriers: G/T or T/T genotypes)
Number of subjects: 185
Study 30309244 — intervention group
Group type: COMPARATOR
Intervention: G/G homozygotes
Number of subjects: 185
Study 28489001 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenergic blockade (40 mg propranolol)
Number of subjects: 0
Study 28489001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor blockade (400 mg amisulpride)
Number of subjects: 0
Study 28489001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25968968 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention system (HIS, OPTILOGG(®)) with a tablet computer and weight scale
Number of subjects: 82
Study 25968968 — intervention group
Group type: COMPARATOR
Intervention: Standard HF information only (Control Group)
Number of subjects: 82
Study 22966986 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-102 (2, 6, 18, 30 and 40 mg single dose; 2, 4 and 8 mg twice daily for 7 days; 1, 2 and 4 mg twice daily for 7 days)
Number of subjects: 0
Study 22966986 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-102
Number of subjects: 0
Study 22966986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 21242462 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 36
Study 18992984 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines 2005
Number of subjects: 40
Study 18992984 — intervention group
Group type: COMPARATOR
Intervention: Guidelines 2000
Number of subjects: 40
Study 16808774 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized health planning (PHP)
Number of subjects: 154
Study 16808774 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 154
Study 14971987 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific performance feedback
Number of subjects: 32
Study 14971987 — intervention group
Group type: EXPERIMENTAL
Intervention: General information
Number of subjects: 32
Study 11720142 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy with duodenal partition
Number of subjects: 30
Study 11720142 — intervention group
Group type: COMPARATOR
Intervention: Antrectomy
Number of subjects: 30
Study 8988926 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15 mg)
Number of subjects: 120
Study 8988926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8241923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure for at least six sessions over 3 weeks
Number of subjects: 186
Study 8241923 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no cue exposure)
Number of subjects: 186
Study 8241923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cue exposure and control)
Number of subjects: 186
Study 8241923 — intervention group
Group type: COMPARATOR
Intervention: Cue exposure and control subjects
Number of subjects: 186
Study 3631029 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg trimoprostil
Number of subjects: 12
Study 3631029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg trimoprostil
Number of subjects: 12
Study 3631029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28784042 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS paired with massed practice training
Number of subjects: 8
Study 28784042 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 8
Study 27812703 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular iPad game (1 hour a day for 16 weeks)
Number of subjects: 385
Study 27812703 — intervention group
Group type: COMPARATOR
Intervention: Patching of the fellow eye (2 hours a day for 16 weeks)
Number of subjects: 385
Study 24728866 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (LSG begins the division 2 cm from the pylorus)
Number of subjects: 105
Study 24728866 — intervention group
Group type: COMPARATOR
Intervention: Group II (LSG begins the division 6 cm from the pylorus)
Number of subjects: 105
Study 24728866 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 105
Study 24728866 — intervention group
Group type: COMPARATOR
Intervention: Group II
Number of subjects: 105